ESMO 2025 – Celcuity fights for a share of the breast cancer market
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
ESMO 2025 – Enhertu’s perioperative Destiny beckons
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
ESMO 2025 – synthetic lethality leaves much to prove
Artios, Synnovation and Novartis show mere glimmers of activity.
ESMO 2025 – Roche sticks it to its SERD rivals
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
ESMO 2025 – Potomac marches step for step with Crest
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Petosemtamab shows first colorectal promise
But more detail is awaited, especially on toxicity.
